Antisense therapeutics: lessons from early clinical trials

The authors review the early clinical experience with antisense oligodeoxynucleotides, documenting their limited toxicity profile and initial reports of efficacy. Several oncogene products, most notably bcl-2, c-raf-1, protein kinase C-&agr;, and H-ras, have been evaluated as targets for therapeutic downregulation, and oligodeoxynucleotides designed to inhibit the expression of these products specifically have been studied extensively in phase I and II trials in cancer patients. Inhibition of target expression in tumor (non-Hodgkin lymphoma) and surrogate tissues has been demonstrated in several of these trials. Continuous infusion over 2 to 3 weeks appears preferable to weekly administration for toxicity and downregulation of target mRNA. The efficacy data available suggest that antisense therapy alone appears capable of limiting disease progression in some patients, but major tumor responses are uncommon. The specificity and tolerability of these oligodeoxynucleotides support the investigation of combinations of antisense oligodeoxynucleotides with cytotoxic chemotherapy, and early combination studies have yielded results of interest. Antisense oligodeoxynucleotides against bcl-2, c-raf-1, and protein kinase C-&agr; continue to be the focus of ongoing trials.

[1]  J. Sloan,et al.  A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  C. Rudin,et al.  Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  I Lebedeva,et al.  Antisense oligonucleotides: promise and reality. , 2001, Annual review of pharmacology and toxicology.

[4]  H. Pehamberger,et al.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy , 2000, The Lancet.

[5]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Nemunaitis,et al.  A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  J. Kurie,et al.  Antisense approaches enter the clinic. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  B. Monia,et al.  Antisense Approaches for the Treatment of Cancer , 2000, Cancer investigation.

[9]  P. O'dwyer,et al.  c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Nemunaitis,et al.  Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Sikic,et al.  Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  P. O'dwyer,et al.  Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Levin,et al.  Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. , 1997, Anti-cancer drug design.

[14]  D. Kornbrust,et al.  Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. , 1997, Toxicology.

[15]  E. Lesnik,et al.  2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[16]  M. Pangburn,et al.  Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. , 1997, The Journal of pharmacology and experimental therapeutics.

[17]  D. Cunningham,et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.

[18]  Doriano Fabbro,et al.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.

[19]  T. Greiner,et al.  Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Crooke,et al.  Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. , 1995, Molecular pharmacology.

[21]  P. Johnson,et al.  Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. , 1994, Oncogene.

[22]  John Calvin Reed,et al.  Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. , 1994, Antisense research and development.

[23]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[24]  John Calvin Reed,et al.  Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. , 1993, Antisense research and development.

[25]  P. Iversen,et al.  Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. , 1993, Antisense research and development.

[26]  B. Calabretta,et al.  Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Calabretta,et al.  An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Calabretta,et al.  A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. , 1988, Science.

[29]  A. Levine,et al.  Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. , 1979, Cancer research.